يعرض 1 - 20 نتائج من 20 نتيجة بحث عن '"interstim"', وقت الاستعلام: 0.49s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
  9. 9
    Academic Journal
  10. 10
  11. 11
    Dissertation/ Thesis
  12. 12
    Academic Journal

    المؤلفون: Ngoc-bich Le, Ja-hong Kim

    المساهمون: The Pennsylvania State University CiteSeerX Archives

    المصدر: ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/be/de/Curr_Bladder_Dysfunct_Rep_2011_Mar_25_6(1)_25-30.tar.gz

    وصف الملف: application/zip

  13. 13
    Academic Journal
  14. 14
    Academic Journal

    وصف الملف: application/pdf

    Relation: Shakuri‐rad, Jaschar; Cicic, Arman; Thompson, Jannah (2018). "Prospective randomized study evaluating ultrasound versus fluoroscopy guided sacral InterStim® lead placement: A pilot study." Neurourology and Urodynamics 37(5): 1737-1743.; https://hdl.handle.net/2027.42/145364; Neurourology and Urodynamics; Noblett K, Siegel S, Mangel J, et al. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2016; 35: 246 â 251.; Chughtai B, Sedrakyan A, Isaacs A, Lee R, Te A, Kaplan S. Long term safety of sacral nerve modulation in medicare beneficiaries. Neurourol Urodyn. 2015; 34: 659 â 663.; Banakhar M, Gazwani Y, Kelini ME, Alâ shaiji T, Hassouna M. Effect of sacral neuromodulation on female sexual function and quality of life: are they correlated ? Can Urol Assoc J. 2015; 8: E762 â E767.; Siegel S, Noblett K, Mangel J, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6â months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015; 34: 224 â 230.; Chai TC, Mamo GJ. Modified techniques of S3 foramen localization and lead implantation in S3 neuromodulation. Urology. 2001; 58: 786 â 790.; Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and healthâ related quality of life questionnaire: the OABâ q. Qual Life Res. 2002; 11: 563 â 574.; Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndromeâ overactive bladder symptom score. Urology. 2006; 68: 318 â 323.; Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000; 43: 9 â 16.; Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of interstim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014; 33: 488 â 492.; Chen TT, Wang C, Ferrandino MN, et al. Radiation exposure during the evaluation and management of nephrolithiasis. J Urol. 2015; 194: 878 â 885.; Taylor ER, Kramer B, Frye TP, Wang S, Schwartz BF, Köhler TS. Ocular radiation exposure in modern urological practice. J Urol. 2013; 190: 139 â 143.; Deters LA, Dagrosa LM, Herrick BW, Silas A, Pais VM. Ultrasound guided ureteroscopy for the definitive management of ureteral stones: a randomized, controlled trial. J Urol. 2014; 192: 1710 â 1713.; Siegel SW, Catanzaro F, Dijkema HE, et al. Longâ term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgencyâ frequency, and retention. Urology. 2000; 56: 87 â 91.; Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (nonâ neurogenic) in adults: aUA/SUFU guideline. J Urol. 2012; 188: 2455 â 2463.; Van kerrebroeck PE, Van voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007; 178: 2029 â 2034.; Peeters K, Sahai A, De ridder D, Van der aa F. Longâ term followâ up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014; 113: 789 â 794.; Deng DY, Gulati M, Rutman M, Raz S, Rodríguez LV. Failure of sacral nerve stimulation due to migration of tined lead. J Urol. 2006; 175: 2182 â 2185.; Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol. 2006; 175: 2178 â 2180.; Lai HH, Grewal S. Bacterial colonization rate of InterStim and infection outcome with staged testing. Urology. 2013; 82: 1255 â 1260.; Alâ zahrani AA, Elzayat EA, Gajewski JB. Longâ term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14â year experience at 1 center. J Urol. 2011; 185: 981 â 986.

  15. 15

    المصدر: The Canadian journal of urology, vol 24, iss 4
    Scopus-Elsevier
    Okhunov, Z; Farhan, B; Ahmed, A; Pulford, C; & Ghoniem, G. (2017). Surgical technique for removal of tined lead for InterStim. Canadian Journal of Urology, 24(4), 8918-8920. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/19r163r9

    وصف الملف: application/pdf

  16. 16
  17. 17
  18. 18
    Academic Journal

    وصف الملف: application/pdf

    Relation: Anger, Jennifer T.; Cameron, Anne P.; Madison, Rodger; Saigal, Christopher; Clemens, J. Quentin (2014). "Predictors of Implantable Pulse Generator Placement After Sacral Neuromodulation: Who Does Better?." Neuromodulation: Technology at the Neural Interface (4): 381-384.; https://hdl.handle.net/2027.42/107552; Neuromodulation: Technology at the Neural Interface; Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 2000; 89: 1792 – 1799.; Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FE. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349: 2117 – 2127.; Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747 – 1751.; Edwards EB, Roberts JP, McBride MA, Schulak JA, Hunsicker LG. The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med 1999; 341: 2049 – 2053.; Hannan EL, O'Donnell JF, Kilburn H Jr, Bernard HR, Yazici A. Investigation of the relationship between volume and mortality for surgical procedures performed in New York State hospitals. JAMA 1989; 262: 503 – 510.; Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003; 21: 401 – 405.; Ellison LM, Heaney JA, Birkmeyer JD. The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol 2000; 163: 867 – 869.; Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138 – 1144.; Yao SL, Lu‐Yao G. Population‐based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 1999; 91: 1950 – 1956.; Dimick JB, Goodney PP, Orringer MB, Birkmeyer JD. Specialty training and mortality after esophageal cancer resection. Ann Thorac Surg 2005; 80: 282 – 286.; Goodney PP, Lucas FL, Stukel TA, Birkmeyer JD. Surgeon specialty and operative mortality with lung resection. Ann Surg 2005; 241: 179 – 184.; McKenna DB, Marioni JC, Lee RJ, Prescott RJ, Doherty VR. A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma. Br J Dermatol 2004; 151: 636 – 644.; Anger JT, Litwin MS, Wang Q, Pashos CL, Rodriguez LV. Variations in stress incontinence and prolapse management by surgeon specialty. J Urol 2007; 178 ( 4 Pt 1 ): 1411 – 1417.; Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ. National trends in the usage and success of sacral nerve test stimulation. J Urol 2011; 185: 970 – 975.; Saigal CS, Pashos CL, Henning JM, Litwin MS. Variations in use of imaging in a national sample of men with early‐stage prostate cancer. Urology 2002; 59: 400 – 404.; Baron JA, Lu‐Yao G, Barrett J, McLerran D, Fisher ES. Internal validation of Medicare claims data. Epidemiology 1994; 5: 541 – 544.; Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ; Urologic Diseases in America Project. Battery explantation after sacral neuromodulation in the Medicare population. Neurourol Urodyn 2013; 32: 238 – 241.; Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology 2005; 66: 746 – 750.; Koldewijn EL, Rosier PF, Meuleman EJ, Koster AM, Debruyne FM, van Kerrebroeck PE. Predictors of success with neuromodulation in lower urinary tract dysfunction: results of trial stimulation in 100 patients. J Urol 1994; 152 ( 6 Pt 1 ): 2071 – 2075.; van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007; 178: 2029 – 2034.; Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev 2009;( 2 ) CD004202.; Leong RK, De Wachter SG, Nieman FH, de Bie RA, van Kerrebroeck PE. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy. Neurourol Urodyn 2011; 30: 1249 – 1252.

  19. 19
    Academic Journal
  20. 20